The Vaxonella® platform
Prokarium’s oral vaccine delivery platform is designed to take an antigen from gene sequence to immune response with a standardised production process, regardless of the type of antigen used. The vaccine is expressed in attenuated strains of Salmonella enterica which have been proven to be safe in clinical trials. The bacteria are ingested, pass through the stomach and then traverse the lining of the small intestine via M cells into lymphatic nodules called Peyer’s patches. There they are phagocytosed by antigen-presenting cells (APCs) such as macrophages, and express the antigen genes. The antigens are processed and presented by the APCs to stimulate humoral and cellular immune responses. The Salmonella are potent immunostimulators, so no additional adjuvant is needed to stimulate a strong, protective immune response.
The Vaxonella® platform incorporates advanced proprietary genetic and formulation technologies that are designed to optimise live bacterial vector-mediated antigen delivery: X-mark™, ORT-VAC™ and BAR™. Our Salmonella vectors have an excellent safety record, demonstrated in pre-clinical studies and clinical trials.